The efficacy of trazodone and clorazepate to relieve anxiety and depressive symptoms in 21 HIV-positive subjects with adjustment disorders was determined in a 28-day singlecentre, randomized, double-blind study. Subjects were evaluated using the Hospital Anxiety and Depression Scale, the Revised Symptom Checklist, the European Organization for Research and the Treatment of Cancer Quality of Life Questionnaire, and a binary criterion based on the Clinical Global Impression. The incidence of successful treatment was 80% for trazodone compared with 64% for clorazepate; the sample number was too small to establish a significant difference. Bayesian analysis revealed the probability of making a wrong decision in prescribing trazodone rather than clorazepate reduced from 35% to 18% in this small sample. Clinical evaluations using the different scales suggest some benefit from trazodone, although this was not significant. Safety of both treatments was similar. Trazodone is devoid of the risk of abuse and dependence, and may be a valuable alternative to benzodiazepines for the treatment of HIV-related adjustment disorders.
INTRODUCTION
The last few years have witnessed a growing appreciation, in terms of diagnosis and management, of neuropsychiatric disorders associated with the acquired immunodeficiency syndrome (AIDS). The profound psychological stress resulting from the knowledge of having a fatal and socially stigmatizing illness can disrupt daily cognitive and affective functioning.' This stress is further complicated by the finding that the human immunodeficiency virus (HIV) itself is neurovirulent and may cause severe cognitive impairment and organic mental disorders." -4 As many as 17% of HIV-infected subjects meet the Diagnostic and Statistical Manual of Mental Disorders (3rd edn., revised; DSM-III-R) criteria for major depression." -7 These psychopathological and neuropsychiatric complications require systematic neurobehavioural assessment that lead to a diagnosis of the emotional disturbances and to a choice of therapeutic interventions." Adjustment disorders with varying mood disturbances are the most common psychiatric diagnosis in subjects with HIV infection, especially in the early course of the disease.
Very few psychotropic medications have been tested in psychiatric complications of AIDS. Benzodiazepines with short-tointermediate onset of action have been evaluated for treating adjustment disorders with single or mixed emotional features; treatment for a brief period of 2 -3 weeks was recommended.P-" Psychostimulants, such as methylphenidate or dextroamphetamine, have been tested in depressed HIV-positive subjects with or without organic mental disorder. lO ,l l In 1995, an uncontrolled pilot study suggested the efficacy of fluoxetine in the treatment of major depression in subjects with HIV infection.V Psychopharmacological intervention offers the most immediate prospect of relief from the stress and distress symptomatology associated with AIDS. Patients with a possible neurological involvement may, however, be at greater risk of developing side-effects because of their greater central nervous system vulnerahility."
To our knowledge, no study has investigated the efficacy and safety of antidepressants in controlling anxiety and depression in HIV-positive subjects with adjustment disorders. Trazodone, a selective serotonin reuptake inhibitor with specific antagonism against 5-HT z (a _ c) postsynaptic receptors, combines antidepressant activity with significant anxiolytic and sedative effects, and has been indicated for the treatment of psychological distress.P In this pilot, double-blind study, we analysed the efficacy and tolerability of trazodone and clorazepate in the treatment of adjustment disorders in HIV-positive subjects.
SUBJECTS AND METHODS

STUDY POPULATION
To be eligible, subjects had to meet the following inclusion criteria: age~18 years; life expectancy well exceeding the study duration; positive blood test for HIV; fulfilment of DSM-III-R criteria for the diagnosis of adjustment disorders with anxiety or depressed mood and/or mixed disturbance of emotion and conduct; and score~14 on the French version of the Hospital Anxiety and Depression Scale (HADS).14,15 Exclusion criteria included: significant history of serious psychiatric disorders, such as major depressive disorder or panic disorder within 1 year prior to study entry; current significant suicide tendency or history of significant suicide attempt; alcohol or drug abuse; other major S De Wit, L Cremers, D Hirsch et al.
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uncontrolled somatic comorbidities; and receipt of psychotropic medications, although zolpidem use was permitted if dosage was constant 7 days prior to study entry. Written informed consent was given by all subjects.
STUDY DESIGN AND DRUG ADMINISTRATION
This study was a single-centre, randomized, double-blind, parallel-group study of 28 days' duration. The study protocol was approved by the Ethics Committee of the Saint-Pierre University Hospital, Belgium, and was conducted in accordance with European Good Clinical Practice guidelines and the current version of the Declaration of Helsinki. At Visit 1 subjects were carefully examined and, after verification of inclusion and exclusion criteria, were randomized using a computer-generated list prepared prior to the start of the study. The dosing schedule was one capsule (containing trazodone 50 mg or clorazepate 10 mg, according to treatment group) on Day 1 and Day 2 of treatment, two capsules on Day 3 and Day 4, and three capsules from Day 5 to Day 28. Capsules were taken orally once daily, either with an evening meal or at bedtime with a snack. The mean daily dosages of trazodone and clorazepate were 97.6 mg/day and 15.6 mg/day, respectively.
TREATMENT EVALUATION
Treatment was evaluated after 14 days (Visit 2) and after 28 days (Visit 3). Assessments were performed using HADS,14,15 the Revised Symptom Checklist (SCL-90-R),16 the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30)l7 and Clinical Global Impression (CGI). The primary endpoint of the study was to determine whether there was a higher incidence 225 of successful responses with trazodone treatment compared with clorazepate treatment. The response was defined as 'successful' if the investigator's CGI was rated 'very much improved', 'improved' or 'minimally improved' (score of 1, 2 or 3, respectively), and if the stated reason for study discontinuation was neither 'failure' nor 'adverse event'. Secondary endpoints were changes in HADS, SCL-90-R, QLQ-C30 scores and subscores, as rated by the subject, compared with baseline (Visit 1).
SAFETY EVALUATION
Physical examinations performed prior to starting the study and at study endpoint identified any changes in body weight, blood pressure and heart rate. Spontaneously reported adverse events were recorded at each interview with the subject.
STATISTICAL ANALYSIS
Subjects were evaluated on an intent-to-treat basis. Changes in SCL-90-R, QLQ-C30 and HADS scores and subscores were assessed between treatment groups using multivariate analysis of variance (MANOVA). Fisher's exact test was used to compare successful responses between treatment groups, and point estimates and 95% confidence intervals (CI) were calculated for the corresponding odds ratio.
Bayesian analysis was used to supplement the classic statistical analysis.!" The parameters of interest in this study were the success probabilities in each treatment group. Therefore, prior to the start of the study, the investigator was interviewed about the plausibility of every possible value for each treatment success probability. These prior opinions or beliefs were then translated into a mathematical form that resulted in the 'prior distribution'. After completion of the study, the results and the prior beliefs were incorporated into the S De Wit, L Cremers, D Hirsch et al.
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analysis and the plausibility of the parameters was updated. These calculations yielded the posterior distribution, from which the ratio of the trazodone success probability to the clorazepate success probability was calculated. This determined the relative risk (RR); equivalence of prior opinions have a value RR = 1.
RESULTS
BASELINE DEMOGRAPHICS
Twenty-three subjects were enrolled; however, two were excluded from analyses as they were lost to follow-up. Ten subjects (two females and eight males) were randomized to receive trazodone. Median age was 36.5 years for females (range: 29 -44), and 27.5 years for males (range: 18 -46); median weight was 64.0 kg for females (range: 61 -69), and 71.0 kg for males (range: 59 -85). Eleven patients (four females and seven males) were randomized to receive clorazepate. Median age was 35.5 years for females (range: 22 -59), and 47.0 years for males (range: 25 -61); median weight was 51.0 kg for females (range: 45 -70), and 64.0 kg for males (range: 52 -86). Demographic data were comparable between the two treatment groups, except that male subjects were older in the clorazepate group compared with the trazodone group (P = 0.04; Wilcoxon test). Of the study population, 13/21 (62%) were homosexual or bisexual; seven of 13 were randomized to receive trazodone and six of 13 to clorazepate. Nine subjects (43%; five of nine in the trazodone group and four of nine in the clorazepate group) were described as regularly exposed to risk factors. Four subjects did not attend all scheduled visits (two from each treatment group) and the last observation was carried forward.
Predominant symptoms included various combinations of anxiety, depression, or other emotions in 16/21 (76%) subjects; two subjects (10%) in the trazodone group and three (14%) in the clorazepate group were diagnosed as suffering from anxiety only. Mean baseline values for HADS, SCL-90-R and QLQ-C30 global scores were comparable between the two treatment groups ( Table 1) . The GSI was also similar in both treatment groups ( Table 2) .
TABLE 1
Subject-rated evaluation of three clinical assessments at baseline and endpoint of study 
CLINICAL EVALUATION
At endpoint, an improvement in HADS, SCL-90-R and QLQ-C30 scores compared with baseline was observed in both treatment groups (Table 1) . A global analysis of HADS scores revealed that the total score decreased earlier in the clorazepate group compared with the trazodone group, but the decrease was more pronounced in the trazodone group (Table 1) . The symptom profile for the SCL-90-R score in each treatment group at baseline and endpoint is shown in Table 2 . The decrease in GSI was more pronounced in the trazodone group compared with the clorazepate group (-0.19 versus -0.12). This study was mainly concerned with evaluating depression, anxiety and phobic anxiety. Improvement in depression symptoms was more marked in the trazodone group in comparison with the clorazepate group (-0.34 versus -0.09)' whereas an effect on anxiety was more pronounced in the clorazepate group (-0.32 versus -0.34). Trazodone also seemed to be more effective than clorazepate in reducing phobic anxiety (-0.34 versus -0.11). Although most of the parameters suggested trazodone to be more favourable, no significant treatment effect was found in this small-sample pilot study (MANOVA).
The improvement in health status and S De Wit, L Cremers, D Hirsch et al. quality of life global score evaluated using the QLQ-C30 scale was very similar, but improvement was marginal in both treatment groups (Table 3 ). The health status and global quality of life score were compared between treatment groups using MANOVA; no significant treatment effect was detected. The percentage of successful responses (as defined in Methods) for trazodone was 80% (eight of 10) and 63.6% (seven of 11) for clorazepate; however, there was no significant difference (P-value = 0.37; Fisher's exact test). The calculated point estimate for the odds ratio was 2.29 (95% CI 0.32; 16.51). Prior to the study, the investigator's opinion regarding successful treatment probabilities gave a slight advantage for trazodone, although prior opinions were less precise for trazodone than for clorazepate. The prior density for 228 RR showed a mode barely above the equivalence point, located at 1.05. Using Bayesian analysis, the prior probability that trazodone was less successful than clorazepate (i.e. RR < 1) was 0.35. After accommodation of prior beliefs and the observed number of successful responses, the posterior mode was updated to 1.13, and the posterior probability that trazodone was less successful than clorazepate was determined to have fallen to 0.18. As shown by robustness analysis, small quantitative changes in the prior distribution did not alter the nature of the conclusions.
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SAFETY
Weight, blood pressure and heart rate were similar at endpoint compared to baseline in the 10 trazodone, and 11 clorazepate-treated subjects evaluated for safety. A higher number of adverse events, and a higher S De Wit, L Cremers, D Hirsch et al. number of adverse events rated as severe, were reported in subjects receiving clorazepate compared with subjects receiving trazodone (Table 4 ). Fourteen subjects (six in the trazodone group and eight in the clorazepate group) reported at least one adverse event, whose relation with study medications was rated as 'probable' (sleepiness, heavy head, vertigo, muscular weakness, dizziness) or 'uncertain' (anxiety, depression, discomfort, sleep disturbances, headache, nausea, swaying, muscular pain, stomach ache, back pain, heavy legs). Adverse events necessitated dose adjustment after 2 weeks of treatment in one of 10 subjects recelvmg trazodone (100 mg to 50 mg/day) and two of 11 subjects receiving clorazepate (50 mg to 10 mg/day).
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After 2 weeks, one subject receiving trazodone withdrew from the study owing to depression and sleepiness and another subject treated with clorazepate withdrew due to sleepiness, heavy head, vertigo and weakness. Two subjects withdrew due to treatment failure; one from each treatment group.
DISCUSSION
Clorazepate is the usual drug of choice for treating adjustment disorders with single or S De Wit, L Cremers, D Hirsch et aI.
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mixed emotional features, but as it is a benzodiazepine derivative it can lead to patient dependence. In the context of HIV infection, which generates new stresses every day, trazodone represents a drug apparently devoid of abuse potential and could be a useful alternative for long-term treatment." In this study, we assessed HIVpositive subjects with an adjustment disorder using four clinical evaluations usually carried out in cancer patients because no specific tests exist for adjustment disorders in HIV-positive subjects.
The SCL-90-R is scored and interpreted in terms of nine primary symptom dimensions (somatization, obsessive--eompulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoia, psychoticism; these parameters provide a broad profile of the subject's status in psycho-pathological terms) and three global indices of distress, including: the Global Severity Index (GSI), a combination of the numbers of symptoms and intensity of perceived distress; the Positive Symptom Total, a count of the number of clinical symptoms the subject reports; and the Positive Symptom Distress Index., a pure intensity measure corrected for the number of symptoms.
Quality of life measured using the QLQ-C30 incorporates nine multi-item scales: five functional scales (physical, role, cognitive, emotional and social); three symptom scales (fatigue, pain and nausea and vomiting); and a global health status and quality of life score. This score ranges from 0 to 100, with a higher score indicating a higher level of functioning.
The proportion of successful treatments was higher (eight of 10) for trazodone than for clorazepate (seven of 11), although this difference was not statistically significant. This may be because there is no 230 treatment-emergent effect or because the increment was not detected from such a small sample number. These conclusions can be implied from Bayesian analysis.
Bayesian analysis, which supplemented the classic statistical analysis owing to the small sample size and the low power of the study, enabled the analyst to assess the treatment differential and provide some conclusions. This approach, however, does not compensate for a small sample number. Bayesian prior beliefs injected into the reasoning that the authors did not expect a marked improvement with trazodone over the reference clorazepate therapy. In prescribing trazodone instead of clorazepate, the authors evaluated that their risk in making the wrong decision was 35%; this was based on the authors' previous experience and knowledge. The higher incidence of successful responses with trazodone compared with clorazepate confirmed prior beliefs and, in addition, when the prior belief was incorporated into the Bayesian analysis, the risk in making the wrong decision reduced to 18%. Whether this decrease is sufficient to replace the reference therapy in preference of trazodone is still a matter of judgement. Factors such as quality of life, safety and other specific effects should also be taken into consideration.
Trazodone seemed to be more effective than clorazepate in reducing psychological distress, assessed by HADS and SCL-90-R global scores, although differences were not significant. Psychological distress was associated with high scores of anxiety and depression in both treatment groups. Compared with subjects in the clorazepate group, subjects receiving trazodone showed a greater reduction in depression mean scores and also a decrease in anxiety mean scores. These observations are consistent with a previous pilot study assessing the benefit of fluoxetine in depressed subjects with HIV Research into the concepts of anxiety and depression treatment and/or control for subjects with HIV infection is in its infancy.
The most common initial reactions to being diagnosed HIV-positive are distress, anger, fear of social abandonment, anxiety concerning loss of body control, pain and death. Decline in self-esteem and suicidal feelings are also frequently observed. Many subjects with HIV experience these reactions intensely for long periods of time." Strategies to reduce psychological stress or to enhance coping capacity include providing information and reassurance, correcting misconceptions, clarifying psychological and social issues, and providing individual supportive psychotherapy. If supportive measures fail to abate the stress/distress symptomatology that can disrupt daily cognitive and affective functioning, pharmacological treatment is mandatory. Short half-life benzodiazepines are recommended in subjects whose anxiety is predominantly reactive in nature and for brief periods (i.e, 2 -3 weeks).8.9For treatment over longer periods of time and in subjects with anxious and depressive symptoms, physicians may consider trazodone as an adjunct to their psychological support.
Recently developed treatments have changed the vital prognosis of HIV-positive subjects, and further studies are necessary to confirm the long-term efficacy and benefits of trazodone, taking into account the different disease stages with or without neurological involvement. Safety is also an essential aspect to consider. It is necessary to improve patient compliance by treating their anxiety and depressive symptoms, and to study the interactions between new HIV treatments and other medications.
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